Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Free Report) CFO Robert Thomas Freeman sold 30,500 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.50, for a total value of $350,750.00. Following the completion of the sale, the chief financial officer now owns 164,109 shares of the company’s stock, valued at approximately $1,887,253.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Robert Thomas Freeman also recently made the following trade(s):
- On Tuesday, October 8th, Robert Thomas Freeman sold 39,320 shares of Alignment Healthcare stock. The shares were sold at an average price of $12.04, for a total value of $473,412.80.
- On Tuesday, October 1st, Robert Thomas Freeman sold 21,375 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.66, for a total transaction of $227,857.50.
- On Friday, September 13th, Robert Thomas Freeman sold 14,500 shares of Alignment Healthcare stock. The stock was sold at an average price of $12.00, for a total transaction of $174,000.00.
- On Wednesday, September 11th, Robert Thomas Freeman sold 8,561 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.01, for a total transaction of $85,695.61.
- On Wednesday, September 4th, Robert Thomas Freeman sold 1,650 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.00, for a total value of $16,500.00.
- On Friday, July 19th, Robert Thomas Freeman sold 38,858 shares of Alignment Healthcare stock. The shares were sold at an average price of $10.01, for a total value of $388,968.58.
Alignment Healthcare Stock Down 4.8 %
Shares of NASDAQ:ALHC opened at $10.88 on Friday. The company has a 50-day moving average price of $10.28 and a 200 day moving average price of $8.33. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 1.70. Alignment Healthcare, Inc. has a 12 month low of $4.46 and a 12 month high of $12.36. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -12.95 and a beta of 1.47.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. purchased a new position in shares of Alignment Healthcare during the 1st quarter worth about $918,000. Vanguard Group Inc. boosted its position in shares of Alignment Healthcare by 1.0% during the first quarter. Vanguard Group Inc. now owns 9,239,472 shares of the company’s stock valued at $45,828,000 after buying an additional 93,262 shares during the period. Deerfield Management Company L.P. Series C boosted its position in shares of Alignment Healthcare by 31.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 10,901,485 shares of the company’s stock valued at $85,250,000 after buying an additional 2,630,788 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Alignment Healthcare by 27.5% during the second quarter. Bank of New York Mellon Corp now owns 382,462 shares of the company’s stock valued at $2,991,000 after buying an additional 82,559 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Alignment Healthcare in the first quarter worth approximately $57,000. Institutional investors own 86.19% of the company’s stock.
Wall Street Analysts Forecast Growth
ALHC has been the topic of a number of research analyst reports. Robert W. Baird boosted their price target on Alignment Healthcare from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Wednesday, August 14th. Piper Sandler reissued an “overweight” rating and issued a $10.00 target price (up previously from $8.00) on shares of Alignment Healthcare in a report on Tuesday, August 6th. KeyCorp assumed coverage on shares of Alignment Healthcare in a research note on Friday, October 11th. They set a “sector weight” rating for the company. TD Cowen boosted their price target on shares of Alignment Healthcare from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, August 6th. Finally, Barclays raised their price objective on Alignment Healthcare from $4.50 to $7.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.83.
Get Our Latest Stock Report on ALHC
Alignment Healthcare Company Profile
Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
See Also
- Five stocks we like better than Alignment Healthcare
- Learn Technical Analysis Skills to Master the Stock Market
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is MarketRank™? How to Use it
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Calculate Options Profits
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.